1 / 15

The concept of Diabetes & CV risk: A lifetime risk challenge

Cardio Diabetes Master Class European chapter Munich, Germany May 6-8, 2011. The concept of Diabetes & CV risk: A lifetime risk challenge. Diabetes & CV Risk: Routine practice versus guidelines. Presentation topic. Slide lecture prepared and held by:. Eberhard Standl, MD

didina
Download Presentation

The concept of Diabetes & CV risk: A lifetime risk challenge

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cardio Diabetes MasterClass Europeanchapter Munich, Germany May 6-8, 2011 The concept of Diabetes & CV risk:A lifetime risk challenge Diabetes & CV Risk: Routine practice versus guidelines Presentation topic Slide lecture prepared and held by: Eberhard Standl, MD Professor of Medicine Munich Diabetes Research Group/ Diabetes Research Institute.MD Munich, Germany

  2. New ESC/EASD Guidelines Investigational algorithm Coronary artery disease (CAD) and diabetes (DM) Main diagnosis CAD ± DM Main diagnosis DM ± CAD CAD unknown ECG, Echocardiography, Exercise test CAD known ECG, Echocardiography, Exercise test Positive finding Cardiology consultation DM unknown OGTT Blood lipids & glucose HbA1c If MI or ACS aim for normoglycemia DM known Screening nephropathy If poor glucose control (HbA1c >6.5%) Diabetology consultation Normal Follow up Newly detected DM or IGT ± metabolic syndrome Diabetology consultation Normal Follow up Abnormal Cardiology consultation Ischemia treatment Noninvasive or invasive

  3. To reach (all) treatment targets including those for glycaemic control • To screen for DM and IGT by means of an OGTT in all patients with coronary artery disease and in other high risk individuals • To let life style counselling be the cornerstone in preventing DM and CVD • To offer patients with DM and ACS standard guideline based treatment, early angiography and mechanical revascularisation • To apply strict, when needed insulin based, glucose control in acutely ill DM patients Ten important recommendations (1)

  4. To favour CABG over PCI when revascularising DM patients • To use drug-eluting stents in PCI with stent implantation • To include investigations for cardiac autonomic dysfunction, heart failure, arrhythmias, hypotension, PVD (Doppler-Index), eGFR and (micro) - albuminuria • To use a multifactorial (tight glucose, BP and lipid-control and antiplatelet therapy) approach • To establish a collaboration between cardiologists and diabetologists Ten important recommendations (2)

  5. Euro Heart Survey Diabetes and the Heart Participating centres 110 from 25 countries n= 4 961 Type of centre: 47% hospital cardiology wards 45% hospital based outpatient clinics 8% outpatient clinics 2- 6 weeks per centre February 2003 to January 2004 (Bartnik et al Eur Heart J 2004; 25:1880-90)

  6. Insulin Oral drugs Combinations No prescription 1% 16% <1% 83% Glycemic control Experiences from the Euro Heart Survey Glucose lowering drugs at follow up in patients with newly detected diabetes Newly detected diabetes n = 452 Prescribed glucose lowering drugs 77 (17%) Not prescribed glucose lowering drugs 375 (83%) (Anselmino et al Eur Heart J 2008;29:177)

  7. Euro Heart Survey Diabetes andthe HeartNewly detected diabetes: Combined cardiovascular events with or without prescribed pharmacological glucose-lowering treatment Anselmino, Malmberg, Standl, Rydén, EuroHeartJ, (2008) 29:177-184 .

  8. 389 39 294 201 Acute admission n=923 (42%) (4%) (32%) (22%) 486 50 320 141 Elective consultation n=997 (49%) (5%) (32%) (14%) Euro Heart Survey Diabetes and theHeart OGTT outcome Patients with coronary artery disease (CAD) and no diabetes (OGTT cohort n=1920) NGT IFG IGT DM <6.1 6.1 and <7.0 <7.0 7.0 OGTT (0 min) <7.8  7.8 and <11.1 or 11.1 OGTT (2 h) <7.8 Bartnik M et al. Eur Heart J 2004;25:1880–1890.

  9. Euro Heart Survey Diabetes andthe HeartFastingand post-loadglycaemia in patientswithCAD andwithoutpreviouslydiagnoseddiabetes (n=1867) Number of patients NGT IGT <5.6 <7.8 5.6-6.1 Dm 7.8-11.1 6.1-7.0 Fasting glycaemia (mmol/l) ≥7.0 ≥11.1 Post-load glycaemia (mmol/l) Bartnik M et al. Heart 2007;93:72–77.

  10. Hyperglycaemia is common and often undiagnosed in patients with CAD in Europeand Asia Euro Heart Survey1 (n=4,961) China Heart Survey2 (n=3,513) 23% 29% 31% 33% 2/3 of patients have hyperglycaemia 3% ~3/4 of patients have hyperglycaemia 24% 12% 21% 25% 20% Normal glucose tolerance Newly diagnosed diabetes Prediabetes (IFG) Previously known diabetes Prediabetes (IGT) CAD: coronary artery disease; OGTT: oral glucose tolerance test; FPG: fasting plasma glucose; IFG: impaired fasting glucose; IGT: impaired glucose tolerance 1. Bartnik M, et al. Eur Heart J 2004;25:1880–90. 2. Hu DY, et al. Eur Heart J 2006;27:2573–9.

  11. Undiagnosed diabetes in the U.S. population aged ≥ 20 years by diagnostic criteria FPG 2.5% 2.5% 0.2% 0.1% 1.2% 0.3% 1.0% A1c 1.6% 2-h glucose 4.9% Cowie CC et al. Diabetes Care 2010

  12. International Expert Committeereport on theroleofthe A1C assay in thediagnosisofdiabetes • A1C ≥ 5.7% to < 6,5% high risk for Diabetes • A1C ≥ 6,5% undiagnosed diabetes • ADA : or FPG > 7.0 mmol/l and/or post load ≥ 11.1 mmol/l Diabetes Care 2009 32: 1327 -1334 WHO position statement 2011: HbA1c > 6.5 diagnostic for DM, levels below do not exclude diagnosis using glucose tests, no formal recommendation to interprete levels < 6.5 %

  13. Type 2 Diabetes: some evidence based recommendations in primary CV prevention 2011 • Evidence for CHD risk equivalence: controversial, but total risk has decreased, i.e. to 10-15% over 10y in the best case scenario vs some 25% with silent myocardial ischemia • Should every diabetic be on low dose aspirin? – probably not (bleeding hazards), however rather limited data base • Should every diabetic be on a statin with a LDL target of 70 mg/dl? – probably yes, but more studies warranted • Should every diabetic be on anti-RAS therapy? Probably yes, but avoid hypotension, especially with preexisting CVD • Silent myocardial ischemia in totally asymptomatic patients with diabetes – is frequent, some 30 %, and with high risk (see above). Appropriate multifactorial therapy plus good medical monitoring for signs and symptoms of CHD effective and economic approach

  14. Multifactorial Intervention in type 2 Diabetes Euro Heart Survey Diabetes and the Heart Impact of Evidence Based Medicine (EBM) on 1-year mortality 1,00 0,99 No DM EBM + 0,98 No DM EBM - 0,97 DM EBM + 0,96 Cumulative survival 0,95 0,94 0,93 DM EBM - 0,92 0,91 0 100 200 300 400 Time of follow up (days) (Anselmino et al Europ J Cardiovasc Prev Rehab 2008;15:216)

  15. Evidence Based Medicine Revascularization Evidence Based No 1826 141 Medicine Yes 24 32 Revascularisation No 105 41 Yes 34 14 Multifactorial Intervention in type 2 Diabetes Euro Heart Survey Diabetes and the Heart NumberNeeded to Treat with EBM and Revascularisation Treatmenttype Diabetes NNT to avoidone event Fatal Cardiovascular (Anselmino et al Europ J Cardiovasc Prev Rehab 2008;15:216)

More Related